期刊
HUMAN MOLECULAR GENETICS
卷 31, 期 1, 页码 10-17出版社
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddab196
关键词
-
资金
- Center for Vascular Anomalies, Freiburg Center for Rare Diseases
- Else-Kroner-Fresenius-Stiftung
- Wissenschaftliche Gesellschaft Freiburg
- Faculty of Medicine, University of Freiburg, Germany
This study investigates the pathogenic factors of vascular malformations, the impact of mutations on the type of malformation, and the use of a zebrafish model for evaluating pathogenicity of mutations and testing candidate drugs in a personalized and mutation-specific approach.
Vascular malformations are most often caused by somatic mutations of the PI3K/mTOR and the RAS signaling pathways, which can be identified in the affected tissue. Venous malformations (VMs) commonly harbor PIK3CA and TEK mutations, whereas arteriovenous malformations (AVMs) are usually caused by BRAF, RAS or MAP2K1 mutations. Correct identification of the underlying mutation is of increasing importance, since targeted treatments are becoming more and more relevant, especially in patients with extensive vascular malformations. However, variants of unknown significance (VUSs) are often identified and their pathogenicity and response to targeted therapy cannot be precisely predicted. Here, we show that zebrafish embryos can be used to rapidly assess the pathogenicity of novel VUSs in TEK, encoding for the receptor TIE2, present on endothelial cells of VMs. Endothelium-specific overexpression of TEK mutations leads to robust induction of VMs, whereas MAP2K1 mutations cause AVMs in our zebrafish model. TEK mutations are often found as double mutations in cis; using our model, we show that double mutations have an additive effect in inducing VMs compared with the respective single variants. The clinically established mTOR-inhibitor sirolimus (rapamycin) efficiently abrogates the development of VMs in this zebrafish model. In summary, endothelium-specific overexpression of patient-derived TEK variants in the zebrafish model allows assessment of their pathogenic significance as well as testing of candidate drugs in a personalized and mutation-specific approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据